Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients

Journal of Immunotherapy

Volumn 30, Issue 8, 2007, Pages 831-838

  Torisu Itakura, Hitoe ^a   Lee, Jonathan H ^a   Huynh, Young ^a   Ye, Xing ^a   Essner, Richard ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Allogeneic whole cell vaccine; Interleukin 10; Melanoma; Monocyte

Indexed keywords

CANVAXIN; CD14 ANTIGEN; INTERLEUKIN 10; MONOKINE;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CRYOPRESERVATION; CYTOKINE RELEASE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; IMMUNIZATION; LYMPHOCYTE; MALE; MELANOMA; MONOCYTE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-10; KAPLAN-MEIERS ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MELANOMA; MIDDLE AGED; MONOCYTES; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; ROC CURVE; TREATMENT OUTCOME;

EID: 37349120720     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318158795b     Document Type: Article

References (33)

1. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
2. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002;20:2045-2052.
3. Pilla L, Valenti R, Marrari A, et al. Vaccination: role in metastatic melanoma. Expert Rev Anticancer Ther. 2006;6:1305-1318.
4. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther. 2006;19:19-25.
5. Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin. 1996;46:225-244.
6. Morton DL, Foshag LJ, Hoon DS, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216:463-482.
7. Chan AD, Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol. 1998;25:611-622.
8. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol. 1998;16:2913-2920.
9. Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol. 1996;3:437-445.
10. Kadison AS, Essner R, Torisu-Itakura H, et al. Cytokine gene expression in surgically resected AJCC stage IV melanoma patients treated with active specific immunotherapy. Ann Surg Oncol. 2003;10:S78.
11. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20:4549-4554.
12. Miyashiro I, Kuo C, Huynh K, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem. 2001;47:505-512.
13. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996;196:137-151.
14. Hsueh EC, Nathanson L, Foshag LJ, et al. Active specific immunotherapy with polyvalent melanoma cell vaccine for patients with in-transit melanoma metastases. Cancer. 1999;85:2160-2169.
15. Kauth M, Grage-Griebenow E, Rohde G, et al. Synergistically upregulated interleukin-10 production in cocultures of monocytes and T cells after stimulation with respiratory Syncytial Virus. Int Arch Allergy Immunol. 2006;142:116-126.
16. Daftarian PM, Kumar A, Kryworuchko M, et al. IL-10 production is enhanced in human T cells by IL-12 and IL-6 and in monocytes by tumor necrosis factor-alpha. J Immunol. 1996;157:12-20.
17. de Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
18. Fuchs AC, Granowitz EV, Shapiro L, et al. Clinical, hematologic, and immunologic effects of interleukin-10 in humans. J Clin Immunol. 1996;16:291-303.
19. Loercher AE, Nash MA, Kavanagh JJ, et al. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol. 1999;163:6251-6260.
20. Howell WM, Turner SJ, Bateman AC, et al. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2:25-31.
21. Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumours. Cancer Lett. 1996;104:1-5.
22. Jebreel A, Mistry D, Loke D, et al. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol. 2007;121:246-252.
23. Nemunaitis J, Fong T, Shabe P, et al. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001;19:239-247.
24. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nat Med. 2002;8:240-246.
25. Torisu H, Ono M, Kiryu H, et al. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: possible involvement of TNFalpha and IL-1alpha. Int J Cancer. 2000;85:182-188.
26. Mirza N, Gabrilovich D. Comment on "cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells" [author reply 4706]. J Immunol. 2007;178:4705-4706.
27. Kryczek I, Wei S, Zou L, et al. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol. 2006;177:40-44.
28. Freedland SJ, Kane CJ, Presti JC Jr, et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. J Urol. 2003;169:969-973.
29. Elia L, Aurisicchio L, Facciabene A, et al. CD4(+)CD25(+) regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge. Cancer Gene Ther. 2007;14:201-210.
30. Morisaki T, Matsumoto K, Onishi H, et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell. 2003;16:175-182.
31. Horvath JC, Horak A, Sinkovics JG, et al. Cancer vaccines with emphasis on a viral oncolysate melanoma vaccine. Acta Microbiol Immunol Hung. 1999;46:1-20.
32. + T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol. 2006;177:7155-7163.
33. - T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol. 2006;67:1-12.